CYTRのチャート
CYTRの企業情報
| symbol | CYTR |
|---|---|
| 会社名 | CytRx Corp （サイトレックス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 サイトレックス(CytRx Corporation)はバイオ医薬品の研究開発会社であり、主に腫瘍学に従事する。同社の腫瘍学薬品パイプラインには、がん適応症向けの「INNO-206」、「tamibarotene」及び「bafetinib」の3つの臨床開発プログラムが含まれる。「INNO-206」は、腫瘍標的ドキソルビシン抱合体である。平成23年5月13日、同社は前臨床および臨床データ、知的財産権、およびそれらの化合物に関連するその他資産を全部Orphazyme ApSに売却した。平成23年12月期決算期において、同社はSynthRxにおける19％の持分をADVENTRX Pharmaceuticalsに売却した。 サイトレックスは米国のバイオ医薬品研究開発会社。主にがんや腫瘍に焦点を当てる。同社は、軟部組織肉腫用の希少疾患用医薬品として広く使われている抗がん剤ドキソルビシンの改良版であるアルドキソルビシンの臨床開発に従事。アルドキソルビジンは徐放性で、腫瘍を選択しながら標的にすることにより、悪性腫瘍を減少させる。本社はロサンゼルス。 |
| 本社所在地 | 11726 San Vicente Blvd. Suite 650 Los Angeles CA 90049 USA |
| 代表者氏名 | Steven A. Kriegsman スティーブンA.クリエンスマン |
| 代表者役職名 | Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者 |
| 電話番号 | +1 310-826-5648 |
| 設立年月日 | 31079 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 1986年 |
| 従業員数 | 17人 |
| url | www.cytrx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/cytr |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -19.69115 |
| 終値（lastsale） | 1.03 |
| 時価総額（marketcap） | 34646626.03 |
| 時価総額 | 時価総額（百万ドル） 34.98300 |
| 売上高 | 売上高（百万ドル） 0.10000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 7.93732 |
| 当期純利益 | 当期純利益（百万ドル） -16.66919 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 CytRx Corporation revenues was not reported. Net loss decreased 72% to $7.1M. Lower net loss reflects Research_Development Expense decrease of 84% to $2M (expense) Gain (loss) on warrant derivative liabil increase from $4.3M (expense) to $527K (income) General and administrative decrease of 35% to $3.3M (expense). |
CYTRのテクニカル分析
CYTRのニュース
CytRx to rename as LadRx 2022/09/23 13:39:47 Seeking Alpha
CytRx (CYTR) said it is renaming as LadRx Corporation, effective Sept
European patent office awards CytRx patent for LADR platform 2022/09/07 14:26:26 Seeking Alpha
CytRx Corporation (CYTR) said on Wednesday it had been awarded a patent by the European Patent Office that covers the incorporation of the LADR backbone in a variety of drug…
CytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock 2022/05/19 20:30:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.01 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 pm Eastern Time on May 20, 2022. The outstanding share
CytRx to absorb subsidiary Centurion BioPharma; former CEO retires from board 2022/03/09 17:24:51 Seeking Alpha
CytRx (CYTR) said it would merge with its subsidiary Centurion BioPharma as the company looks to benefit from Centurion''s LADR platform, which is being developed for localized delivery…
Analyzing Vir Biotechnology (NASDAQ:VIR) & CytRx (OTCMKTS:CYTR) 2021/12/24 10:08:45 Dakota Financial News
Vir Biotechnology (NASDAQ:VIR) and CytRx (OTCMKTS:CYTR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, valuation, dividends, risk and profitability. Volatility & Risk Vir Biotechnology has a beta of -1.48, suggesting that its stock price is 248% []
Trading - Financial Survey: Vir Biotechnology vs. CytRx 2021/12/22 08:59:07 Business Mag
Vir Biotechnology and CytRx are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst
Financial Survey: Vir Biotechnology (NASDAQ:VIR) vs. CytRx (OTCMKTS:CYTR) 2021/12/22 08:46:42 ETF Daily News
Vir Biotechnology (NASDAQ:VIR) and CytRx (OTCMKTS:CYTR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership. Volatility and Risk Vir Biotechnology has a beta of -1.48, indicating that its stock price is 248% [] The post Financial Survey: Vir Biotechnology (NASDAQ:VIR) vs. CytRx (OTCMKTS:CYTR) appeared first on ETF Daily News .
CytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock 2022/05/19 20:30:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.01 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 pm Eastern Time on May 20, 2022. The outstanding share
CytRx to absorb subsidiary Centurion BioPharma; former CEO retires from board 2022/03/09 17:24:51 Seeking Alpha
CytRx (CYTR) said it would merge with its subsidiary Centurion BioPharma as the company looks to benefit from Centurion''s LADR platform, which is being developed for localized delivery…
Analyzing Vir Biotechnology (NASDAQ:VIR) & CytRx (OTCMKTS:CYTR) 2021/12/24 10:08:45 Dakota Financial News
Vir Biotechnology (NASDAQ:VIR) and CytRx (OTCMKTS:CYTR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, valuation, dividends, risk and profitability. Volatility & Risk Vir Biotechnology has a beta of -1.48, suggesting that its stock price is 248% []
Trading - Financial Survey: Vir Biotechnology vs. CytRx 2021/12/22 08:59:07 Business Mag
Vir Biotechnology and CytRx are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst
Financial Survey: Vir Biotechnology (NASDAQ:VIR) vs. CytRx (OTCMKTS:CYTR) 2021/12/22 08:46:42 ETF Daily News
Vir Biotechnology (NASDAQ:VIR) and CytRx (OTCMKTS:CYTR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership. Volatility and Risk Vir Biotechnology has a beta of -1.48, indicating that its stock price is 248% [] The post Financial Survey: Vir Biotechnology (NASDAQ:VIR) vs. CytRx (OTCMKTS:CYTR) appeared first on ETF Daily News .